Abstract

High grade gliomas (HGG) are one of the most common central nervous system (CNS) tumors encountered in adults, but they only represent approximately 8–12% of all pediatric CNS tumors. Historically, pediatric HGG were thought to be similar to adult HGG since they appear histologically identical; however, molecular, genetic, and biologic data reveal that they are distinct. Similar to adults, pediatric HGG are very aggressive and malignant lesions with few patients achieving long-term survival despite a variety of therapies. Initial treatment strategies typically consist of a gross total resection (GTR) when feasible followed by focal radiotherapy combined with chemotherapy. Over the last few decades, a wealth of data has emerged from basic science and pre-clinical animal models helping to better define the common biologic, genetic, and molecular make-up of these tumors. These data have not only provided a better understanding of tumor biology, but they have also provided new areas of research targeting molecular and genetic pathways with the potential for novel treatment strategies and improved patient outcomes. Here we provide a review of pediatric non-brainstem HGG, including epidemiology, presentation, histology, imaging characteristics, treatments, survival outcomes, and an overview of both basic and translational research. An understanding of all relevant pre-clinical tumor models, including their strengths and pitfalls is essential in realizing improved patient outcomes in this population.

Highlights

  • High grade gliomas (HGG) represent one of the most common central nervous system (CNS) tumors among adults

  • HGG include a variety of heterogeneous lesions with differing histologies, but the most common histologies are anaplastic astrocytoma (WHO Grade III) and glioblastoma multiforme (GBM; World Health Organization (WHO) grade IV)

  • We review the current understanding of pediatric HGG biology and current models utilized to assess these tumors

Read more

Summary

Jason Fangusaro*

Over the last few decades, a wealth of data has emerged from basic science and pre-clinical animal models helping to better define the common biologic, genetic, and molecular make-up of these tumors. These data have provided a better understanding of tumor biology, but they have provided new areas of research targeting molecular and genetic pathways with the potential for novel treatment strategies and improved patient outcomes. We provide a review of pediatric non-brainstem HGG, including epidemiology, presentation, histology, imaging characteristics, treatments, survival outcomes, and an overview of both basic and translational research. An understanding of all relevant pre-clinical tumor models, including their strengths and pitfalls is essential in realizing improved patient outcomes in this population

INTRODUCTION
CONCLUSION
Open Label Dose Escalation Safety
Findings
Radiation Therapy Followed by Bevacizumab and Temozolomide in Young
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call